Pfizer's RA drug Xeljanz fails to win EU panel support

04/26/2013 | PharmaTimes (U.K.) · Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against approving Pfizer's rheumatoid arthritis drug Xeljanz, or tofacitinib. The drug improved patients' physical function and RA symptoms but it failed to sufficiently demonstrate "a consistent reduction in disease activity and structural damage to joints," the committee said. Pfizer plans to appeal the recommendation.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA